Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Sarcoma 1Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, B-Cell 2Vascular Diseases 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Mature B-cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia, Lymphoid 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hemostatic Disorders 1Hemorrhagic Disorders 1Dendritic Cell Sarcoma, Interdigitating 1Cardiovascular Diseases 1Blood Protein Disorders 1

Interventions

Rituximab 416Cyclophosphamide 348Vincristine 173Prednisone 172Doxorubicin 168Etoposide 160Peripheral Blood Stem Cell Transplantation 114Filgrastim 108Lenalidomide 97fludarabine phosphate 96Radiotherapy 80Cytarabine 80Gemcitabine 73Melphalan 66Mycophenolic Acid 64Cyclosporine 60Methotrexate 59Busulfan 57Ifosfamide 55Carmustine 55fludarabine 50Tacrolimus 50Whole-Body Irradiation 49Carboplatin 49polatuzumab vedotin 44Oxaliplatin 44Dexamethasone 44Antilymphocyte Serum 42ibrutinib 40Bendamustine Hydrochloride 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × ARQ531 × Clear all
NCT06863402 2026-05-20

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Roswell Park Cancer Institute

Phase 2 Recruiting
32 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡